Medicine information · No products for sale
Mounjaro: Tirzepatide Medicine Information
Factual information about Mounjaro, a tirzepatide-containing prescription medicine.
Published 20 October 2026 · Last reviewed 20 October 2026 · Editorial content by the Peptide Atelier UK team, not clinically reviewed
Editorial standards and corrections
Educational information only. Mounjaro is a prescription-only medicine. Peptide Atelier UK does not sell, supply or prescribe it. This page is not medical advice; speak to a GP, pharmacist or other qualified healthcare professional.
Active ingredient
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. It is given as a once-weekly injection.
Authorised uses
Mounjaro is authorised in the UK for adults with type 2 diabetes and for weight management in adults who meet specific criteria, alongside diet and physical activity.
Safety and contraception
Common side effects include nausea, diarrhoea and reduced appetite. The MHRA has highlighted the importance of effective contraception while using tirzepatide. Read the patient information leaflet and discuss any concerns with your prescriber.
UK prescription requirements
Mounjaro can only be supplied against a valid prescription. Buying it from unregulated sellers risks receiving counterfeit or contaminated products.